Why Aren’t Weight-Loss Drugs Like Ozempic and Wegovy Effective for Everyone?

A multidisciplinary team at the University of Alberta is investigating why people respond differently to semaglutide, focusing on energy metabolism, metabolic adaptation, and changes in body composition. Research shows that, when combined with lifestyle interventions, GLP-1 medications can produce an average weight loss of 15% over 68 weeks, but the effects of semaglutide on resting energy expenditure remain inconclusive. The team is recruiting participants with dysglycemia who are about to begin semaglutide treatment and will follow them for six months using whole-room indirect calorimetry, with the aim of exploring personalized approaches to obesity and type 2 diabetes management.

Source:ScienceDaily · Read Original